PDS Biotechnology Corp (FRA:EU6)
€ 3.234 0.172 (5.62%) Market Cap: 114.22 Mil Enterprise Value: 75.04 Mil PE Ratio: 0 PB Ratio: 3.51 GF Score: 33/100

PDS Biotechnology Post-ASCO Conference Call - Corporate Analyst Meeting Transcript

Jun 08, 2021 / 12:00PM GMT
Release Date Price: €8.17 (-22.02%)
Operator

Hello, and welcome to the PDS Biotechnology Post ASCO Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Deanne Randolph, Vice President, Commercial Development. Please go ahead.

Deanne Randolph
PDS Biotechnology Corporation - VP of Commercial Development & Head of IR

Good morning, and welcome to PDS Biotechnology's Post ASCO webcast. With me today are Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Lauren V. Wood, Chief Medical Officer; and Dr. Seth Van Voorhees, Chief Financial Officer.

Earlier this morning, PDS Biotech issued a press release summarizing the data presented yesterday afternoon at the American Society of Clinical Oncology Annual Meeting. The company's press release is available on PDS Biotech's website at pdsbiotech.com, and a recording of this webcast will be posted to the website later today and will be archived there for future reference.

Before we begin, I would like to caution listeners that comments made by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot